Nutshell Therapeutics' NTS231 Gains FDA IND Clearance as Second NRF2 Degrader to Enter Clinical Development
核心洞察
Nutshell Therapeutics (搜索) received FDA IND clearance for NTS231 (搜索), a covalent allosteric molecular glue degrader of NRF2 (搜索), to begin clinical development in the United States.
NTS231 (搜索) is the first NRF2 (搜索) degrader from China and the second globally to enter clinical development, reaching IND approval 24 months after target nomination.
Preclinical data show dose-dependent single-agent activity in LUSC, LUAD, ESCC and HNSCC models, plus synergy with chemotherapy, targeted agents and ADCs.
Nutshell Therapeutics (搜索) (Shanghai) Co., Ltd. has received FDA IND clearance for NTS231 (搜索), a covalent allosteric molecular glue degrader of NRF2 (搜索), allowing clinical development to start in the United States. NTS231 is the first NRF2 degrader molecule from China and the second globally to enter clinical development. The program targets the NRF2 pathway, which the company describes as a key driver of tumor survival and treatment resistance across multiple cancer types.
The molecule was identified through the company's AI-driven allosteric drug discovery platform, ALLOSTAR, which combines computer-aided drug design, medicinal chemistry and experimental techniques. NTS231 (搜索) covalently binds the Cys151 residue of KEAP1 (搜索), stabilizing a KEAP1 conformation that favors CUL3 (搜索) interaction and assembly of a functional KEAP1-CUL3 E3-ligase complex, thereby driving NRF2 (搜索) degradation and suppressing NRF2 signaling. IND approval was achieved within 24 months of target nomination.
In preclinical work, NTS231 (搜索) showed non-inferior in vitro activity to VVD-130037, a clinical-stage compound with the same targeting mechanism, with superior pharmacokinetic properties. Dose-dependent single-agent antitumor efficacy was seen across cell-derived and patient-derived xenograft models carrying diverse NRF2 (搜索)/KEAP1 (搜索)/CUL3 (搜索) mutations or NRF2 hyperactivation, including lung squamous cell carcinoma (搜索), lung adenocarcinoma (搜索), esophageal squamous cell carcinoma (搜索) and head and neck squamous cell carcinoma (搜索). Synergy was observed with chemotherapy, targeted therapies and antibody-drug conjugates, including enhanced tumor growth inhibition with paclitaxel in chemotherapy-resistant LUSC PDX models and tumor regression with a TROP2 ADC (搜索) in an NFE2L2 (搜索)-amplified LUAD model. In 28-day GLP toxicology studies in rats and dogs, NTS231 showed a favorable safety profile and a wide safety margin.
Approximately 12% of cancer patients profiled in the TCGA database carry mutations in NFE2L2 (搜索), KEAP1 (搜索) or CUL3 (搜索), with prevalence above 30% in LUSC and above 20% in LUAD, and preliminary estimates indicate over 1.5 million annual new cancer cases worldwide harbor NRF2 (搜索)/KEAP1/CUL3 alterations or other aberrant NRF2 pathway activation. These alterations are mutually exclusive with EGFR, ALK, ROS1 and BRAF lesions, and are associated with an immunologically cold tumor microenvironment and resistance to standard chemotherapy.
Source: Manila Times / PR Newswire